Asthma and COPD HRV Human Viral Challenge Studies

Asthma and COPD HRV Human Viral Challenge Studies

Contract Research

Information

hVIVO has been leading the human viral challenge movement for respiratory viruses. We have begun to conduct HRV challenge studies in subjects with respiratory conditions that are exacerbated by viral infection, such as Asthma and COPD. These models are very specific to the mechanism of action of your drug candidate and we would be happy to discuss designing a study specific to your needs in this area.
hVIVO​hVIVO plc (“hVIVO”), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

Log in